Form 4: RVMD CEO Executes Options, Sells Shares in Planned Trades

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported exercising stock options, selling 30,000 shares, and transferring 100,000 shares to family trusts, all executed under a pre-arranged 10b5-1 trading plan.

Summary

• Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., exercised stock options to acquire 26,479 shares at $1.12 per share and 3,521 shares at $4.09 per share on November 7, 2025.
• On the same date, Mr. Goldsmith sold 30,000 shares of common stock at a weighted average price of $60.3102 per share.
• On November 12, 2025, Mr. Goldsmith transferred 50,000 shares to the Jonathan Goldsmith Revocable Trust and another 50,000 shares to the Rebecca Goldsmith Revocable Trust, both at a price of $0.
• All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.
• Following these transactions, Mr. Goldsmith directly holds 247,863 shares and indirectly holds shares through various trusts, including 70,424 shares via Jonathan Goldsmith Revocable Trust, 54,498 shares via Rebecca Goldsmith Revocable Trust, 15,926 shares via Rebecca Eve Goldsmith Trust, and 570,050 shares via Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
• His direct holdings also include 193,475 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about immediate negative signals. The transfers to trusts are for estate planning, and the option exercises represent a profitable event for the insider.

Positives

• The exercise of stock options at significantly lower prices ($1.12 and $4.09) compared to the market sale price ($60.3102) indicates a profitable transaction for the insider.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting a planned liquidity event or diversification strategy rather than a reaction to new, undisclosed negative information.

Negatives

• The sale of 30,000 shares by the President and CEO could be perceived negatively by some investors, as insider selling might sometimes signal a lack of confidence, despite being part of a 10b5-1 plan.

Risks

• Insider selling, even when pre-planned, can sometimes lead to negative market sentiment or speculation, potentially impacting the company's stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider trading activities.

Industry Context

This filing is an individual insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects personal financial planning and liquidity management by a key executive.

Comparison to Industry Standards

• N/A. This filing reports individual insider transactions and does not contain company performance metrics or operational results that can be compared to industry benchmarks or specific comparable companies/projects.

Related Party Transactions

• Transfer of 50,000 shares to the Jonathan Goldsmith Revocable Trust.
• Transfer of 50,000 shares to the Rebecca Goldsmith Revocable Trust.
• Indirect beneficial ownership through Jonathan Goldsmith Revocable Trust, Rebecca Goldsmith Revocable Trust, Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares, even under a 10b5-1 plan, as a signal, potentially influencing short-term trading decisions.
• The transfers to family trusts are primarily for estate planning and do not directly impact employees, customers, suppliers, or creditors.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this insider transaction report.

Key Dates

Recommendation

A Form 4 filing, particularly one detailing transactions under a pre-arranged 10b5-1 plan, typically reflects an insider's personal financial planning rather than a direct signal about the company's immediate operational performance or future prospects. While the sale of shares by a CEO can sometimes raise questions, the planned nature of the transaction suggests it's not a reaction to new, adverse information. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, warranting a 'hold' position for investors to await further fundamental company updates.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Options, Share Sale, Trust Transfer, 10b5-1 Plan, CEO Transactions